Gene-expression assay → chemotherapy omission
A gene test on the tumour decides who can skip chemotherapy without losing protection.
TAILORx (RS ≤25, node-negative) and RxPONDER (RS ≤25, 1-3 nodes, postmenopausal) show no chemotherapy benefit; MINDACT (MammaPrint) concurs. Premenopausal women with intermediate scores still benefit, possibly via ovarian suppression.
Pages like this
not linked directly; found by shared links- PersonKathy S. Albain
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- IdeaA formal regulatory route for validating a biomarker on archived trial samples
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX.
- InstitutionMontefiore Einstein Comprehensive Cancer Center
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- InstitutionWinship Cancer Institute of Emory University
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
- PersonRené Bernards
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- CompanyExact Sciences (Abbott)
Shares Oncotype DX, HR-positive / HER2-negative breast cancer.
- TermOvarian function suppression (OFS)
Shares RxPONDER (SWOG S1007), HR-positive / HER2-negative breast cancer.
- ProductVinorelbine
Shares Cytotoxic chemotherapy, HR-positive / HER2-negative breast cancer.